Livmarli (Maralixibat Chloride) Patent Expiration, LOE Window & CMS Spending
Livmarli (Maralixibat Chloride) by Mirum Pharmaceuticals: FDA Orange Book LOE 2040-02-12, 0 AB generics, $92.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mirum Pharmaceuticals |
| FDA Application & Pathway | N214662 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-02-12 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $92.1M |
| 2024 Medicare Part D Spend | $7.9M |
| 2024 Medicaid Spend | $84.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 21.7% 2-yr change) |